Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Capricor Therapeutics, Inc. (CAPR : NSDQ)

• Company Description    Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. Number of Employees: 48

• Price / Volume Information    Yesterday's Closing Price: $3.06 Daily Weekly Monthly 20 Day Moving Average: 100,364 shares Shares Outstanding: 24.32 (millions) Market Capitalization: $74.43 (millions) Beta: 5.35 52 Week High: $6.22 52 Week Low: $2.56 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.99% 1.53% 12 Week -33.33% -27.95% Year To Date 4.44% 23.70%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10865 Road to the Cure Suite 150 - San Diego,CA 92121 USA ph: 310-358-3200 fax: 415-875-7075 jallaire@lifesciadvisors.com http://www.capricor.com

• General Corporate Information    Officers Linda Marban - Chief Executive Officer and Director Frank Litvack - Executive Chairman and Director Anthony J. Bergmann - Chief Financial Officer Earl M. Collier - Director Louis V. Manzo - Director Peer Information Capricor Therapeutics, Inc. (BJCT) Capricor Therapeutics, Inc. (CADMQ) Capricor Therapeutics, Inc. (APNO) Capricor Therapeutics, Inc. (UPDC) Capricor Therapeutics, Inc. (IMTIQ) Capricor Therapeutics, Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 14070B309 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/11/22 Share - Related Items Shares Outstanding: 24.32 Most Recent Split Date: 6.00 (0.10:1) Beta: 5.35 Market Capitalization: $74.43 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.10 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.02 Price/Cash Flow: - Price / Sales: 232.60 EPS Growth vs. Year Ago Period: -39.13% vs. Previous Quarter: -23.08% Sales Growth vs. Year Ago Period: 308.00% vs. Previous Quarter: 397.56% ROE 03/31/22 - -71.96 12/31/21 - -58.10 09/30/21 - -53.48 ROA 03/31/22 - -47.95 12/31/21 - -47.70 09/30/21 - -44.69 Current Ratio 03/31/22 - 4.16 12/31/21 - 8.82 09/30/21 - 13.82 Quick Ratio 03/31/22 - 4.16 12/31/21 - 8.82 09/30/21 - 13.82 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - -11,122.06 12/31/21 - -8,172.65 09/30/21 - -5,943.90 Book Value 03/31/22 - 1.01 12/31/21 - 1.30 09/30/21 - 1.60 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©